Evidence map›Paper›PMID 30949442›Full record

ReviewWorld journal of clinical oncology2019

Malignant hepatic vascular tumors in adults: Characteristics, diagnostic difficulties and current management.

Daniela Cornelia Lazăr, Mihaela Flavia Avram, Ioan Romoșan, Violetta Văcariu, Adrian Goldiș, Mărioara Cornianu

Open access · diamondAbstract readReview
In one paragraph

Review in World journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Primary hepatic angiosarcoma: a systematic review.Annals of medicine and surgery (2012) · 2024
    Review
  7. Vascular tumors of the liver: A brief review.Annals of hepato-biliary-pancreatic surgery · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Liver transplantation in malignant disease.World journal of clinical oncology · 2021
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Hepatic Hemangioendothelioma: An update.World journal of gastrointestinal oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniela Cornelia LazărDepartment of Internal Medicine I, University Medical Clinic, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Romania.
Mihaela Flavia AvramDepartment of Surgery X, 1 Surgery Clinic, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Romania. avram.mihaela@umft.ro.
Ioan RomoșanDepartment of Internal Medicine I, University Medical Clinic, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Romania.
Violetta VăcariuDepartment of Internal Medicine I, University Medical Clinic, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Romania.
Adrian GoldișDepartment of Gastroenterology and Hepatology, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Romania.
Mărioara CornianuDepartment of Pathology, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Romania.
Victor Babeș University of Medicine and Pharmacy Timișoara · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant vascular tumors of the liver include rare primary hepatic mesenchymal tumors developed in the background of a normal liver parenchyma. Most of them are detected incidentally by the increased use of performing imaging techniques. Their diagnosis is challenging, involving clinical and imaging criteria, with final confirmation by histology and immunohistochemistry. Surgery represents the mainstay of treatment. Liver transplantation (LT) has improved substantially the prognosis of hepatic epithelioid hemangioendothelioma (HEHE), with 5-year patient survival rates of up to 81%, based on the European Liver Intestine Transplantation Association-European Liver Transplant Registry study. Unfortunately, the results of surgery and LT are dismal in cases of hepatic angiosarcoma (HAS). Due to the disappointing results of very short survival periods of approximately 6-7 mo after LT, because of tumor recurrence and rapid progression of the disease, HAS is considered an absolute contraindication to LT. Recurrences after surgical resection are high in cases of HEHE and invariably present in cases of HAS. The discovery of reliable prognostic markers and the elaboration of prognostic scores following LT are needed to provide the best therapeutic choice for each patient. Studies on a few patients have demonstrated the stabilization of the disease in a proportion of patients with hepatic vascular tumors using novel targeted antiangiogenic agents, cytokines or immunotherapy. These new approaches, alone or in combination with other therapeutic modalities, such as surgery and classical chemotherapy, need further investigation to assess their role in prolonging patient survival. Personalized therapeutic algorithms according to the histopathological features, behavior, molecular biology and genetics of the tumors should be elaborated in the near future for the management of patients diagnosed with primary malignant vascular tumors of the liver.

Indexed as

DiagnosticHepatic angiosarcomaHepatic epithelioid hemangioendotheliomaHepatic hemangiopericytomaHepatic malignant vascular tumorsHepatic perivascular epithelioid cell tumorHepatic small vessel neoplasiaKaposi sarcomaPrognosticTreatment

Identifiers

PMID30949442
PMCPMC6441663
OpenAlexW2923407379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.